Medexus Pharmaceuticals Inc. (TSE:MDP) Forecasted to Post Q1 2026 Earnings of $0.23 Per Share

Medexus Pharmaceuticals Inc. (TSE:MDP) – Analysts at Raymond James issued their Q1 2026 earnings estimates for shares of Medexus Pharmaceuticals in a research note issued to investors on Wednesday, June 26th. Raymond James analyst R. Sarugaser forecasts that the company will post earnings of $0.23 per share for the quarter. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.25 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q2 2026 earnings at $0.25 EPS, Q3 2026 earnings at $0.25 EPS, Q4 2026 earnings at $0.26 EPS and FY2028 earnings at $1.15 EPS.

Separately, Ventum Cap Mkts raised Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday.

Medexus Pharmaceuticals Stock Performance

MDP opened at C$1.82 on Friday. The stock’s 50 day moving average price is C$1.67 and its 200-day moving average price is C$1.88. Medexus Pharmaceuticals has a one year low of C$1.44 and a one year high of C$3.53. The stock has a market cap of C$44.52 million, a price-to-earnings ratio of 4.55 and a beta of 1.82.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.